{"\u2022TMB-H": [0], "failed": [1, 258, 327, 557, 627], "to": [2, 9, 66, 73, 79, 135, 138, 202, 259, 280, 328, 365, 372, 378, 433, 436, 501, 558, 579, 628], "predict": [3, 20], "improved": [4], "or": [5], "clinically": [6], "relevant": [7], "response": [8, 21, 65, 165, 364, 463], "ICB": [10, 47, 88, 157, 203, 339, 387, 455, 502, 639], "in": [11, 48, 102, 128, 216, 340, 401, 426, 515, 640], "all": [12, 49, 117, 341, 416, 641], "cancer": [13, 50, 178, 235, 343, 477, 534, 643], "types.\u2022Cancer": [14], "types": [15, 179, 236, 478, 535], "where": [16, 180, 479], "TMB-H": [17, 42, 92, 196, 256, 332, 391, 495, 555, 632], "does": [18], "not": [19, 112, 295, 411, 594], "generally": [22], "show": [23], "no": [24, 239, 538], "relationship": [25, 240, 539], "between": [26, 145, 241, 298, 443, 540, 597], "tumor": [27, 53, 77, 104, 346, 352, 376, 403, 646], "neoantigen": [28, 147, 187, 246, 445, 486, 545], "load": [29, 148, 446], "and": [30, 119, 141, 149, 171, 193, 245, 254, 273, 318, 439, 447, 469, 492, 544, 553, 572, 617], "CD8": [31, 150, 181, 242, 448, 480, 541], "T-cell": [32, 182, 243, 481, 542], "infiltration.\u2022Further": [33], "studies": [34, 348, 648], "should": [35], "be": [36], "carried": [37], "out": [38], "before": [39], "application": [40, 330, 630], "of": [41, 87, 108, 154, 302, 331, 386, 407, 452, 601, 631], "as": [43, 60, 94, 190, 249, 322, 333, 359, 393, 489, 548, 621, 633], "a": [44, 61, 199, 261, 275, 323, 334, 360, 498, 560, 574, 622, 634], "biomarker": [45, 63, 110, 335, 362, 409, 635], "for": [46, 64, 76, 90, 307, 336, 363, 375, 389, 606, 636], "types.": [51, 344, 644], "BackgroundHigh": [52], "mutation": [54, 353], "burden": [55, 354], "(TMB-H)": [56, 355], "has": [57, 111, 356, 410], "been": [58, 113, 357, 412], "proposed": [59, 358], "predictive": [62, 361], "immune": [67, 366], "checkpoint": [68, 367], "blockade": [69, 368], "(ICB),": [70, 369], "largely": [71, 370], "due": [72, 371], "the": [74, 97, 106, 143, 299, 373, 396, 405, 441, 598], "potential": [75, 374], "mutations": [78, 377], "generate": [80, 379], "immunogenic": [81, 380], "neoantigens.": [82, 381], "Despite": [83, 382], "recent": [84, 383], "pan-cancer": [85, 384], "approval": [86, 385], "treatment": [89, 158, 337, 388, 456, 637], "any": [91, 390], "tumor,": [93, 392], "assessed": [95, 394], "by": [96, 162, 315, 319, 395, 460, 614, 618], "targeted": [98, 397], "FoundationOne": [99, 398], "CDx": [100, 399], "assay": [101, 400], "nine": [103, 402], "types,": [105, 404], "utility": [107, 406], "this": [109, 408], "fully": [114, 413], "demonstrated": [115, 414], "across": [116, 415], "cancers.Patients": [118], "methodsData": [120], "from": [121, 419], "over": [122, 420], "10": [123, 421], "000": [124, 422], "patient": [125, 308, 423, 607], "tumors": [126, 197, 220, 257, 282, 303, 424, 496, 519, 556, 581, 602], "included": [127, 425], "The": [129, 427], "Cancer": [130, 428], "Genome": [131, 429], "Atlas": [132, 430], "were": [133, 294, 313, 431, 593, 612], "used": [134, 432], "compare": [136, 434], "approaches": [137, 435], "determine": [139, 437], "TMB": [140, 155, 218, 321, 438, 453, 517, 620], "identify": [142, 440], "correlation": [144, 442], "predicted": [146, 444], "T": [151, 449], "cells.": [152, 450], "Association": [153, 451], "with": [156, 186, 338, 454, 485, 638], "outcomes": [159, 457], "was": [160, 210, 458, 509], "analyzed": [161, 459], "both": [163, 461], "objective": [164, 462], "rates": [166, 464], "(ORRs,": [167, 465], "N": [168, 175, 466, 473], "=": [169, 176, 224, 265, 271, 284, 290, 305, 467, 474, 523, 564, 570, 583, 589, 604], "1551)": [170, 468], "overall": [172, 470], "survival": [173, 471], "(OS,": [174, 472], "1936).ResultsIn": [177], "levels": [183, 244, 482, 543], "positively": [184, 483], "correlated": [185, 484], "load,": [188, 247, 487, 546], "such": [189, 248, 488, 547], "melanoma,": [191, 490], "lung,": [192, 491], "bladder": [194, 493], "cancers,": [195, 494], "exhibited": [198, 274, 497, 573], "39.8%": [200, 499], "ORR": [201, 263, 278, 500, 562, 577], "[95%": [204, 503], "confidence": [205, 504], "interval": [206, 505], "(CI)": [207, 506], "34.9-44.8],": [208, 507], "which": [209, 508], "significantly": [211, 276, 296, 510, 575, 595], "higher": [212, 511], "than": [213, 512], "that": [214, 237, 513, 536], "observed": [215, 514], "low": [217, 516], "(TMB-L)": [219, 518], "[odds": [221, 520], "ratio": [222, 521], "(OR)": [223, 522], "4.1,": [225, 524], "95%": [226, 267, 286, 525, 566, 585], "CI": [227, 268, 287, 526, 567, 586], "2.9-5.8,": [228, 527], "P": [229, 270, 289, 528, 569, 588], "<": [230, 529], "2": [231, 530], "\u00d7": [232, 531], "10\u221216].": [233, 532], "In": [234, 476, 533], "showed": [238, 537], "breast": [250, 549], "cancer,": [251, 253, 550, 552], "prostate": [252, 551], "glioma,": [255, 554], "achieve": [260, 559], "20%": [262, 561], "(ORR": [264, 563], "15.3%,": [266, 565], "9.2-23.4,": [269, 568], "0.95),": [272, 571], "lower": [277, 576], "relative": [279, 578], "TMB-L": [281, 580], "(OR": [283, 582], "0.46,": [285, 584], "0.24-0.88,": [288, 587], "0.02).": [291, 590], "Bulk": [292, 591], "ORRs": [293, 592], "different": [297, 596], "two": [300, 599], "categories": [301, 600], "(P": [304, 603], "0.10)": [306, 605], "cohorts": [309, 608], "assessed.": [310, 609], "Equivalent": [311, 610], "results": [312, 611], "obtained": [314, 613], "analyzing": [316, 615], "OS": [317, 616], "treating": [320, 619], "continuous": [324, 623], "variable.ConclusionsOur": [325], "analysis": [326, 626], "support": [329, 629], "solid": [342, 642], "Further": [345, 645], "type-specific": [347, 647], "are": [349, 649], "warranted.": [350, 650], "High": [351], "cancers.": [417], "Data": [418], "1936).": [475], "variable.": [624], "Our": [625]}